Mood Disorders News

A 4-week induction course of esketamine nasal spray may still benefit patients with treatment-resistant depression who did not exhibit a response in the first week of treatment.

The continued use of electroconvulsive therapy appeared warranted for reducing suicide risk among patients with severe depression, according to results of a registry-based cohort study published in JAMA Network Open.

Preexisting mental disorders, particularly psychotic and mood disorders, as well as exposure to antipsychotics and anxiolytics, increased risk for COVID-19-related mortality.

Electroconvulsive therapy for depression did not lead to a clinically significant increased risk for serious medical events, according to results of a propensity score-matched, retrospective cohort study published in The Lancet Psychiatry.

Vortioxetine more effectively improved depression, anxiety and cognition than placebo, according to study results published in Journal of Clinical Psychiatry.

Following imposed lockdowns and remote schooling in Austria, adolescents experienced significantly lower mental health and life satisfaction in 2021 compared with 2018, according to a cross-sectional study published in JAMA Network Open.

Groups with shorter fetal maturity at birth had slightly higher rates of multiple neuropsychiatric disorders while groups with the longest fetal maturity exhibited the lowest rates for most disorders.

A neuroactive steroid in pill form significantly reduced depressive symptoms and was generally well-tolerated among women with postpartum depression, according to results of a randomized clinical trial published in JAMA Psychiatry.

Researchers conducted an umbrella review of interventions for mental disorders among youths that provided evidence-based information for clinical decision making.

Esmethadone, a once-daily pill for major depressive disorder, demonstrated rapid, robust and sustained antidepressant effects.